ACAD ▼ -19.5% - ACADIA Pharmaceuticals Inc.
$ACAD Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
24-SEP-2026 07:00 AM ET
Share this post
More filings for $ACAD
ACAD ▼ -1.1% - Acadia Pharmaceuticals Inc.Sep 28, 2026ACAD - ACADIA Pharmaceuticals Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026
View full $ACAD filing history →💬 Comments
Loading comments…
Leave a comment